Kiniksa (KNSA) Form 144: Insider to Sell 3,523 Shares Worth $124K

Kiniksa Pharmaceuticals International, plc (KNSA) reported a Form 144 notice for a proposed sale of 3,523 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $124,397.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) reported a Form 144 notice for a proposed sale of 3,523 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $124,397. The filing shows the shares were acquired by restricted stock lapse as equity compensation on 09/01/2025 (3,010 shares) and 09/02/2025 (513 shares). The company’s total outstanding Class A shares are listed as 43,472,928, and the sale is scheduled approximately for 09/04/2025. The notice contains the standard attestations about absence of undisclosed material information and compliance with Rule 144 and Rule 10b5-1 disclosures.

Positive

• Disclosure compliance: The filer submitted a Form 144 detailing the proposed sale and acquisition dates, meeting Rule 144 requirements.
• Source of shares disclosed: Shares arose from equity compensation (restricted stock lapse), which clarifies the origin of the securities.
• Transaction size is immaterial: 3,523 shares represent a negligible portion of 43,472,928 outstanding shares, suggesting limited market impact.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider proposes a small post-vesting sale representing a tiny fraction of outstanding shares; disclosure is routine and likely non-material.

The Form 144 shows an insider sale of 3,523 shares valued at $124,397 following recent restricted stock lapses. Relative to 43.47 million shares outstanding, the proposed sale is immaterial in size (<0.01%), reducing the likelihood of market-moving impact. The filing meets Rule 144 disclosure requirements and includes the standard representation about no undisclosed material information. Investors typically view such post-vesting sales as liquidity events rather than votes of non-confidence, though monitoring aggregate insider activity remains prudent.

Corporate Governance Expert

TL;DR: The notice documents compliance with insider sale rules after equity vesting; governance disclosure procedures appear followed.

The tables indicate these shares resulted from equity compensation vesting on 09/01/2025 and 09/02/2025 and will be sold via a registered broker on 09/04/2025. The filer executed the standard attestation about material information and references Rule 10b5-1 where applicable, which aligns with good governance practices for insider transactions. Because the amounts are small relative to total float, this filing does not signal a significant governance concern by itself.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 3,523 Class A ordinary shares via Charles Schwab with an aggregate market value of $124,397, approximately scheduled for 09/04/2025.

How were the KNSA shares acquired that are being sold?

The shares were acquired through restricted stock lapse as equity compensation: 3,010 shares on 09/01/2025 and 513 shares on 09/02/2025.

How large is the proposed sale relative to Kiniksa's outstanding shares?

The proposed sale of 3,523 shares is a very small fraction of the reported 43,472,928 outstanding Class A shares (<0.01% of the float).

Is there any report of other securities sold by the same person in the past three months?

The filing indicates "Nothing to Report" for securities sold during the past three months by the person for whose account the securities will be sold.

Which broker is handling the proposed sale for KNSA?

The broker listed is Charles Schwab & Co., Inc. located at 3000 Schwab Way, Westlake, TX 76262.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 04:51 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001857177
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	23 OLD BOND STREET, FLOOR 3 LONDON UNITED KINGDOM WIS 4PZ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Moat Ross
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	3523	124397.00	43472928	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	09/01/2025	Restricted Stock Lapse	Kiniksa Pharmaceuticals, Ltd.			3010	09/01/2025	Equity Compensation
Class A ordinary shares	09/02/2025	Restricted Stock Lapse	Kiniksa Pharmaceuticals, Ltd.			513	09/02/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/04/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/13/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ross Moat
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)